Why Clinical Trials Matter in the Search for Type 1 Diabetes Solutions

Breakthrough T1D, a leading research and advocacy organization, has expanded its strategic focus by adding medical affairs as a new pillar of work. This shift reflects a growing recognition that advancing Type 1 diabetes care requires coordination across multiple approaches—not just better management tools, but fundamentally new ways to prevent and treat the disease.

According to Anastasia Albanese O'Neal, vice president of medical affairs at Breakthrough T1D, the organization is now thinking deliberately about what she calls an "emerging care paradigm" for Type 1 diabetes. This paradigm rests on three interconnected pillars of research and development.

The first pathway focuses on screening and early detection. By identifying people at risk for Type 1 diabetes before symptoms appear, researchers hope to intervene earlier in the disease process.

The second involves immunotherapies designed to stop the immune system from attacking and destroying the beta cells that produce insulin. These therapies aim to preserve remaining beta cell function or prevent the loss of function altogether.

The third pathway looks toward manufactured cell therapies—approaches that could eventually replace insulin-producing beta cells for people who can no longer make their own. This represents a longer-term research goal but one that could transform treatment for people living with Type 1 diabetes.

Each of these three approaches—early detection, immunotherapy, and cell replacement—depends on rigorous clinical research to move from concept to safe, effective treatment. Clinical trials are the bridge between laboratory discoveries and real-world care.

Without people willing to participate in research studies, these promising approaches cannot be tested, refined, or ultimately made available to the broader Type 1 diabetes community. Participation helps answer critical questions about safety, effectiveness, and which patients benefit most from which approaches.

This expanded focus signals that Type 1 diabetes research is moving beyond diabetes management alone. While insulin, pumps, and continuous glucose monitors remain important tools, the field is increasingly oriented toward preventing disease onset, halting disease progression, and eventually restoring beta cell function.

For people newly diagnosed, at risk, or living with Type 1 diabetes, this shift creates new possibilities—and new reasons to stay informed about clinical research opportunities in your area.

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.